SEOM clinical guideline for treatment of kidney cancer (2019)

• M. Lázaro ^[1] ; B. P. Valderrama ^[2] ; C. Suárez ^[8] ; G. de-Velasco ^[3] ; C. Beato ^[9] ; I. Chirivella ^[10] ; A. González-del-Alba ^[4] ; N. Laínez ^[5] ; M. J. Méndez-Vidal ^[6] ; J. A. Arranz ^[7]
  1. [1] Complexo Hospitalario Universitario de Vigo

     Complexo Hospitalario Universitario de Vigo

     Vigo, España

     
  2. [2] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  3. [3] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  4. [4] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  5. [5] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  6. [6] IRB Barcelona - Institute for Research in Biomedicine

     IRB Barcelona - Institute for Research in Biomedicine

     Barcelona, España

     
  7. [7] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  8. [8] Hospital Universitario Vall d’Hebron
  9. [9] Hospital Universitario Virgen de la Macarena
  10. [10] Hospital Clínico Valencia

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 2 (February), 2020 (Ejemplar dedicado a: Clinical Guides in Oncology), págs. 256-269
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • In this article, we review de state of the art on the management of renal cell carcinoma (RCC) and provide recommendations on diagnosis and treatment. Recent advances in molecular biology have allowed the subclassification of renal tumours into different histologic variants and may help to identify future prognostic and predictive factors. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. No adjuvant therapy has demonstrated a clear benefit in overall survival. Considering the whole population of patients with advanced disease, the combination of axitinib with either pembrolizumab or avelumab increase response rate and progression-free survival, compared to sunitinib, but a longer overall survival has only been demonstrated so far with the pembrolizumab combo. For patients with IMDC intermediate and poor prognosis, nephrectomy should not be considered mandatory. In this subpopulation, the combination of ipilimumab and nivolumab has also demonstrated a superior response rate and overall survival vs. sunitinib. In patients progressing to one or two antiangiogenic tyrosine-kinase inhibitors, both nivolumab and cabozantinib in monotherapy have shown benefit in overall survival compared to everolimus. Although no clear sequence can be recommended, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in patients with metastatic RCC.